BrainsWay (BWAY) vs Cerus (CERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cerus (CERS) has outperformed BrainsWay (BWAY) over the past year, gaining 14.2% versus a gain of 13.9%. Over five years, BWAY leads with a +130.7% price change compared with -73.5% for CERS. Cerus is the larger company by market cap ($373.6 million vs $341.3 million), about 1.1 times the size, while BrainsWay is growing revenue faster (+29.0% vs +16.1%).
On valuation, BrainsWay trades at a lower forward P/E (17.0x vs 123.3x for Cerus). BrainsWay converts more of its revenue into profit, with a net margin of 7.1% versus -6.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BWAY | CERS |
|---|---|---|
| Share price | $8.48 | $1.85 |
| Market cap | $341.35M | $373.62M |
| 1-day change | -2.86% | -2.63% |
| YTD return | -10.83% | -10.19% |
| 1-year return | +13.90% | +14.20% |
| 5-year return | +130.75% | -73.50% |
| P/E ratio (TTM) | 35.33 | — |
| Forward P/E | 16.96 | 123.33 |
| EPS (TTM) | $0.24 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.02M | $233.80M |
| Revenue growth (YoY) | +29.04% | +16.13% |
| Net income (latest FY) | $2.92M | $-15.63M |
| Gross margin | 74.56% | — |
| Operating margin | 3.39% | -3.71% |
| Net margin | 7.12% | -6.68% |
| 52-week high | $17.40 | $3.47 |
| 52-week low | $7.30 | $1.59 |
| Distance from 52-week high | -51.26% | -46.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +127.24% | +177.30% |
| Average volume | 110.35K | 2.12M |
| Shares outstanding | 40.25M | 201.95M |
| Employees | 129 | 261 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BrainsWay is more profitable, keeping 7.1 cents of every revenue dollar as net income versus -6.7 cents for Cerus.
- BrainsWay grew revenue faster in its latest fiscal year (+29.04% vs +16.13%).
About BrainsWay
BWAY stock →BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 129 employees
About Cerus
CERS stock →Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Health Care · Medical/Dental Instruments · 261 employees
BWAY vs CERS FAQ
Which is bigger, BrainsWay or Cerus?
Cerus (CERS) is larger, with a market capitalization of $373.62M compared with $341.35M for BrainsWay (BWAY).
Which stock has performed better over the past year, BWAY or CERS?
CERS returned +14.20% over the past 12 months, compared with +13.90% for BWAY (price return, excluding dividends). Past performance does not predict future results.
Are BrainsWay and Cerus in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.